Clinical Impact of Uterine Repair During Cesarean Section with Barbed Suture on the Incidence of Isthmocele

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorHospital Clinic of Barcelona

About this trial

Pregnant women, irrespective of their pregnancy risk, who undergo a cesarean section for any reason will be randomized to one of two suturing techniques: conventional suture or barbed suture for uterine repair after the cesarean section. Following surgery, these patients will be followed up for clinical outcomes, ultrasound evaluation of the uterine scar, and study of the hypoxic-inflammatory environment of the uterine cavity.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Pregnant women who deliver at Hospital Clinic of Barcelona by a planned, intrapartum or urgent cesarean section, irrespective of their pregnancy risk.

Had accepted to participate in the study during the third trimester of gestation.

Patients who accept a 6-month follow-up visit.

Minimal maternal age of 18 years old.

Disqualifiers

Patients who end up delivering in another center.

Patients who deliver by vaginal route.

Patients diagnosed with isthmocele prior to the current pregnancy.

Need for histerectomy in the following 6 months after delivery.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Barbed suture

    Device

    Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.

  • Conventional smooth suture

    Device

    Size 1 smooth multifilament absorbable polyglactin suture.

Treatment groups

364 Participants
are divided into 2 treatment groups
Group A: Study Group: Uterine repair with barbed sutureExperimental treatment 1 intervention
Group B: Control Group: Uterine repair with conventional smooth sutureActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Rate of Isthmocele

Rate of isthmocele six months after cesarean section examined by transvaginal ultrasonography with hysterosonography.

Time frame
Six months after cesarean section.
2

Ultrasonographic Measurements of Isthmocele

Ultrasonographic characteristics of isthmocele measured by niche length, niche depth, niche width, residual myometrial thickness (RMT) and niche size (niche depth/niche depth+RMTx100\[%\]).

Time frame
Six months after cesarean section.

Secondary outcomes

1

Intrauterine molecular markers of hypoxia and inflammation

Concentrations of the following biomarkers will be assessed by analyzing an endocavitary lavage of the uterus: VEGF-A (an indirect marker of tissue hypoxia associated with angiogenesis and vasculogenesis), G-CSF, IL-1β, IL-6, IL-10, and TNF-α (inflammatory cytokines), as well as HIF1A (hypoxia-inducible transcription factor).

Time frame
Six months after cesarean section.
2

Symptoms

Evaluation of symptoms related to CSD six months after cesarean section, measured as the presence of one or more of the following: prolonged postpartum bleeding, spotting, abnormal menstrual bleeding, dysmenorrhea, pelvic pain and/or dyspareunia.

Time frame
Six months after cesarean section.
3

Risk factors

Collection of individual data in relation to the patient characteristics and the surgical procedure to evaluate potential risk factors. Individual data: Age at inclusion, ethnicity, educational level, parity, number of cesarean deliveries, history of uterine surgery or other abdominal surgeries, body mass index, smoking status, gestational or pregestational diabetes, hypertension, other medical conditions. Surgical data: Location of the hysterotomy, need for additional hemostatic sutures, need for hemostatic material at the surgical site, requirement for antifibrinolytic or uterotonic treatment to control bleeding, estimated blood loss during the surgery.

Time frame
Through study completion, an average of 2 years.
4

Ultrasonographic myometrial texture patterns

Time frame
Six months after cesarean section.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.